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ABSTRACT
Treatment of cardiac disease via the epicardium fell under the domain of cardiac surgery due to the need for an open thoracot-
omy. Since an open thoracotomy is invasive in nature and has the potential for complications, a minimally invasive and percu-
taneous approach would be more attractive for suitable patients. The recent success of epicardial ablation of refractory ar-
rhythmia via the percutaneous pericardial approach has increased the potential for delivery of epicardial therapies. Epicardial 
ablation has increased the success and safety since anti-coagulation and transseptal catheterization for left atrial arrhythmias is 
not required. The pericardial space has also been used to deliver therapy for several cardiac diseases. There are reports on 
successful delivery of drugs and their efficacy. Even though there was a wide range of efficacies reported in those studies, the 
reported complication rates are strikingly low, which suggests that direct delivery of drugs to the epicardium via the pericar-
dial space is safe. Furthermore, recent animal studies have supported the feasibility of epicardial delivery of biological agents, 
including genes, cells, and even genetically engineered tissue for therapeutic purposes. In conclusion, percutaneous pericardi-
al cannulation of closed pericardial space can play a significant role in providing non-surgical therapy for cardiovascular dis-
eases. However, it requires skills and operator experiences. Therefore, there is need to further develop new tools, safer tech-
niques, and effective procedure environment before generalizing this procedure. (Korean Circ J 2010;40:479-488)
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Introduction
In the past, the epicardium was targeted for delivery of th-
erapeutic agents, such as drugs, pacing leads, and devices in 
conjunction with an intended cardiac surgery to treat a vari-
ety of cardiovascular diseases via thoracotomy. The risk of 
potential complications related to thoracotomy made this 
approach less attractive for use as a routine procedure for 
non-cardiac surgery patients. In particular, the risk in patients 
who require multiple procedures can be significant, due to 
the extensive fibrosis as a result of a previous thoracotomy. 
In recent years, invasive cardiac procedures via a closed pe-
ricardium have been proven to be safe and effective, particu-
larly in the cardiac electrophysiology arena.
1) Theoretically, a 
minimally invasive percutaneous approach that can provide 
the possibility of multiple procedures without causing signifi-
cant fibrosis of the pericardium or other complications, may 
offer significant advantages for cardiac therapies performed 
via the epicardium. Other potential advantages of a pericardi-
al approach are that it is possible to achieve a high concentra-
tion with longer duration of drugs due to the small confined 
space without any circulatory blood flow. Furthermore, it 
provides the views needed to guide delivery of an intended 
therapy, and minimize the risk of bleeding or strokes, because 
there is no need for anti-coagulation therapy. 
The pericardial sac can be used as a diagnostic source for 
many cardiac and non-cardiac conditions, such as pericardial 
effusions from neoplastic or inflammatory processes. In some 
instances, epicardial biopsy guided by a pericardial scope wo-
uld be useful for making a histological diagnosis.
2)
The pericardium has much autonomic innervation and neu-
ro-receptors that closely interact with cardiac contraction and 480   Percutaneous Epicardial Therapies
coronary circulation. The mesothelial cells of the visceral 
pericardium have active metabolic activity, including cyclo-
oxygenation and lipo-oxygenation. It is well known that 
prostanoids can alter the tone of the pericardial sympathetic 
neurons that influence myocardial contractility and coronary 
artery dilatation. There are many other potential physiologic 
roles that could be used for cardiac disease therapies.
However, as the currently practiced percutaneous cannu-
lation technique for accessing a closed pericardium is still in 
the early stage of development, it has significant limitations 
and the technique needs to be tested for its safety and repro-
ducibility. The important considerations of this review in-
clude the procedure for accessing a closed pericardial sac via 
the percutaneous approach, exploring the potential usage of 
this approach to treat cardiac diseases, and address the future 
development of new tools to meet the needs of the cardio-
vascular therapies.
Anatomy of Pericardial Sac
The pericardial sac consists of two layers with nerves, lym-
phatics, and blood vessels. The sac normally contains 20 to 40 
mL of clear fluid that occupies the virtual space between the 
two layers, which are divided into the visceral and parietal 
pericardium. The visceral pericardium covers the entire epi-
cardial surface, except for a small area on the posterior wall 
of the atria, and is composed of a single layer of mesothelial 
cells. The pericardial sac folds cover the major proximal ves-
sels and the entire epicardial surface is accessible from the 
pericardial space, except for the atrial and ventricular septa 
which are not in direct contact with the pericardium.
3)
The pericardial sac has attachments to the posterior medi-
astinum formed by the oblique and transverse sinuses, which 
in turn form several recesses that fold over the great arteries 
and veins
4-8) as shown in Fig. 1.
9) There are several anatomi-
cal variations of these recesses, as shown in Fig. 2.
10) 
The layer not attached to the epicardium is the parietal pe-
ricardium. The parietal pericardium is much thicker and is 
composed predominantly of acellular fibrotic tissue that is 
rich in collagen. However, it has blood vessels and a dense in-
nervation, including the autonomic and mechano-chemical 
receptors. The parietal pericardium is firmly attached to the 
anterior mediastinum and diaphragm through tendon-like 
fibrotic tissues. These attachments are essential to maintain 
normal cardiac position in relation to the surrounding struc-
tures, to restrict the volume of thin-walled cardiac chambers 
(right ventricle and right atrium), and also to serve as direct 
protection against injuries.
11) The pericardium secrets several 
prostaglandin-like substances that may play an important role 
in the control of the autonomic and coronary vascular tones.
12)
Pericardial Sac Cannulation
Clinical considerations
Percutaneous access of a closed pericardial sac has been suc-
cessfully performed by the endocardial and epicardial appro-
aches. The endocardial approach can be achieved by a punc-
ture of the tip of the right atrial appendage with a small caliber 
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Fig. 1. A: the anatomy of the pericardium and its reflections along the great vessels, sinuses, and recesses are shown in an anterior view af-
ter removing the heart. The superior sinus (superior aortic recess) lies anterior to the upper ascending aorta and the main pulmonary artery. 
The transverse sinus is limited by the pericardial reflection between the superior pulmonary veins, and contains the RPA. The oblique sinus 
is confined by the pericardial reflections around the pulmonary veins and the IVC. The PCR lies behind the SVC, RPA, and right superior 
pulmonary vein. The RPVR, LPVR extend between their respective superior and inferior pulmonary veins. The white areas indicate the bare 
regions between the reflections of the serous pericardium. B: the transverse sinus and its right inferior extension (anterior view). The inferior 
aortic recess allows access to the epicardial portion of the ascending aorta related to the non-coronary cusp and the inferior aspect of the 
right coronary cusp.
9) RPA: right pulmonary artery, IVC: inferior vena cava, PCR: postcaval recess, SVC: superior vena cava, RPVR: right 
pulmonary vein recesses, LPVR: left pulmonary vein recesses, LPA: left pulmonary artery, IAR: inferior aortic recess.Seongwook Han, et al.   481
needle, which enables access to the anterior region of the peri-
cardial sac. Contrast can be injected to confirm the pericardi-
al space. A guide-wire can then be placed and using an over-
the-guidewire technique, a gradual dilatation of the puncture 
site can be performed to insert the desired diameter of sh-
eath.
13) Two epicardial approaches have been reported. One 
of which is the anterior parasternal approach to access the an-
terior region of the pericardial sac through the left intercos-
tal spaces, which is less frequently practiced due higher com-
plications observed. The most frequently used method is the 
sub-xyphoid approach reported by Sosa et al.
1) This technique 
is the preferred approach by most investigators, and has been 
the basis for future technological development. There are se-
veral studies reporting new technologies that enable safer 
percutaneous access of the pericardial space, but no large-sc-
ale clinical data is available.
14)
There are several contra-indications or conditions associ-
ated with higher risk complication risks from percutaneous 
cannulation of a closed pericardial sac. 
These conditions are discussed below:
Previous cardiac surgery or pericardial surgery including
pericardiectomy
Previous cardiac surgery usually results in significant peri-
cardial fibrosis, and the pericardial space is virtually replaced 
by fibrotic adhesions. Percutaneous cannulation of the peri-
cardial sac is very difficult, even in the case of a successful can-
nulation, the manipulation of instruments is extremely lim-
ited and difficult. The preferred approach in these patients is 
a hybrid method and it is discussed in the subsequent pages.
Congenital absence of the pericardium 
Congenital absence of the pericardium was recognized by 
Columbus
15) and by Baille.
16) These anomalies are the result 
of premature atrophy of the left duct of Cuvier, and prema-
ture reduction of blood supply to the left pleuropericardial 
membrane.
17) The incidence is 1 in 14,000, and predomi-
nantly involves partial absence of the left pericardium.
18) 
About one third of the cases occur with other congenital 
malformations, both cardiac and non-cardiac.
19-21) Chest ra-
diograph is key to diagnosis and has been the basis of the 
earliest clinical recognition of the congenital absence of the 
pericardium. The first diagnosis using chest radiograph was 
reported by Ellis et al.
22) Chest radiograph findings can be 
confirmed with CT or MRI scans (Fig. 3A).
23-25)
Pericardial varices 
Pericardial varices are often observed in patients with pro-
ximal venous occlusive disease, particularly associated with 
superior vena cava syndrome.
26) On rare occasions, portal hy-
pertension can be associated with not only pericardial, but 
also mediastinal varices that can increase the risk of bleed-
ing (Fig. 3B). 
Fig. 2. Variations in the pulmonary venous pericardial recesses (posterior view). The white areas indicate uncovered areas between the re-
flections of the serous pericardium. The most common anatomic variant is the presence of both right and left pulmonary venous pericardial re-
cesses. A, B-type was seen in more than half of the patients studied.
9) IVC: inferior vena cava, OS: oblique sinus, SVC: superior vena cava.
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Pericardial cysts 
Rare abnormalities in these areas are often diagnosed in-
cidentally during routine chest radiographs that are mostly 
located in the apical regions, which can be confirmed by CT 
scan.
27) The cysts can be large enough to interfere with cannul-
ation. 
Pericardial fat necrosis 
This is a rare condition, better known in the cardiac surgi-
cal field and can present with atypical chest pain. There are few 
case reports available and the recommended management 
of choice is surgery.
28)29) 
Hiatal hernia 
The presence of a hiatal hernia, especially of large size, can 
result in inadvertent perforation during cannulation attempts. 
Such perforation is often associated with mediastinal infec-
tions.
Ascites 
Besides the bleeding risk associated with liver disease and 
pericardial varices, the trajectory of cannulation of the peri-
cardial sac can unintentionally cause invasion of the abdom-
inal cavity when penetrating the diaphragmatic aspect of the 
pericardial sac. The presence of a large ascites may result in 
post-procedural persistent drainage, which can be challeng-
ing to manage.
Complications associated with the pericardial 
cannulation 
Percutaneous cannulation of a closed pericardium requires 
much experience in order to avoid complications. Several se-
rious complications have been associated with this puncture 
technique, including hemothorax, cardiac perforation with he-
mopericardium, and abdominal viscus perforation. Rarely, 
complications can occur after successful cannulation due to 
mechanical trauma to the myocardium, including VT and VF, 
cardiac vein lacerations, and pericarditis.
Pre-procedure evaluation
Evaluation should include comprehensive clinical assess-
ment and imaging studies to recognize any pre-existing con-
traindications, and to minimize complications. Chest radio-
graph, echocardiography, and cardiac MRI have proven to 
be useful for screening these patients.
Procedure environment
The procedure is usually performed in cardiac catheter-
ization or electrophysiology laboratories. However, in view 
of the complexity of the patient’s clinical condition and that of 
the procedure, a hybrid laboratory where cardiac surgery can 
be performed promptly would be the ideal setting.
Cannulation technique
Intravenous antibiotics should be used routinely in these 
Fig. 3. Congenital absence of the left pericardium and pericardial varices. A: an anteroposterior tomogram of the chest documenting the inter-
position of the lungs between the aorta and pulmonary artery (arrow). B and C: a magnified CT scan through the great vessels (B) showing the 
rotation of the main pulmonary artery segment out of the mediastinal fat, with resulting interposition of air between the aorta and prominent 
pulmonary artery (arrow). Compare this appearance to the normal anatomy in another patient (C). D: a magnified CT scan at the level of the 
heart demonstrates the abrupt termination of the right pericardium at the site of the indentation of the cardiac contour (arrow) where the heart 
bulges into the left chest.
23) E: CT scan of a patient with a superior vena cava obstruction. An axial volume-rendered maximum-intensity-projec-
tion CT scan through the lower heart and liver showing a left-to-right pericardiophrenic arcade. A continuous arcade is seen going counter-
clockwise from the left pericardiophrenic vein (open white arrow) to the left inferior phrenic vein (thick arrow), to the inferior vena cava (i), thence 
anteriorly via intrahepatic collaterals (open black arrows) to create a blush of contrast material in the quadrate lobe (solid black arrow), and 
thence to the right inferior phrenic (short white arrow) and pericardiophrenic veins (long white arrow).
25)
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patients and given within an hour prior to the procedure. The 
components of the pericardial sac cannulation tray are shown 
in Fig. 4. The puncture site is identified based on the anatomi-
cal landmarks, as shown in Fig. 5A. The puncture needle ap-
proaches the site with a shallow angle in order to penetrate 
the skin and slide under the rib cage, and is re-oriented accord-
ing to the targeted puncture site (Fig. 5B, C and D). The sty-
let is then removed, and a 10 mL syringe containing 1% lidoc-
aine (3 to 5 mL) is attached to the proximal port of the need-
le. The needle is advanced gradually under fluoroscopy while 
infiltrating with lidocaine, which should be done after gentle 
aspiration to avoid injecting into any vessels. This maneuver 
is repeated until the parietal pericardium is reached. It is use-
ful to confirm the needle orientation in three different views: 
anteroposterior, left anterior oblique (LAO), and right ante-
rior oblique (RAO) views. The LAO view confirms the ante-
rior versus posterior orientation (right and left cardiac cham-
bers) (Fig. 6A) and the RAO view confirms the superior and 
inferior orientation (atria and ventricles) (Fig. 6B). Once the 
cardiac pulsation is felt with the needle tip, the lidocaine sy-
ringe is removed and a syringe that contains 2 to 3 mL of non-
ionic contrast agent is attached. The puncture needle is care-
fully advanced toward the pericardial space, and often one 
can feel the “pop” as the needle penetrates the fibrotic pari-
etal pericardial wall and then a small volume (<1 mL) of con-
trast is injected into the pericardial space to confirm success-
ful puncture (Fig. 6C). A long soft “J” tip guide wire is then ad-
vanced far enough to silhouette the pericardial space (Fig. 6D).
The puncture needle is removed and an 8F dilator is ad-
vanced over the guide wire under fluoroscopic guidance (Fig. 
7A and B) to achieve pre-dilatation prior to insertion of an 
8.5F angled along the braided sheath (Swartz Braided SL1, 
St. Jude Medical, St. Paul, MN, USA) (Fig. 7C and D). The 
long sheath with the dilator is advanced or manipulated 
Fig. 4. The components of a standard pericardial cannulation tray. A: 
scalpel. B: 10 cc syringe with 1% lidocaine. C: 10 cc syringe with a con-
trast agent. D: Tuohy Point Epidural Needle with a stylet. E: J sh-
aped guide wires. F: short sheath for the initial access. G: dilator for 
a long sheath. H: long sheath. I: magnified view of the tip of the Tuo-
hy needle.
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Fig. 5. Puncture technique 1. A: the junction of the xyphoid process and left lower costal margin is a good site for the pericardial puncture. B: the 
angle of skin puncture should be narrow to advance the needle under the rib-cage. C: if the angle is wide, there is risk of injuring the abdominal 
organs. D: once the needle is placed under the rib cage, the direction can be redirected depending on the target chamber.
4)
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with the guide wire to reach the target area, followed by dila-
tor removal. The angle of the sheath used should be less than 
20° to avoid laceration of epicardial structures. The pericar-
dial sheath is gently aspirated to obtain a yellowish clear peri-
cardial fluid that confirms non-traumatic cannulation of the 
pericardial sac. Pericardial fluid can then be sampled for re-
search purposes. 
We performed a pericardiogram (Fig. 8) using 5 mL of a 
non-ionic contrast mixed with steroid (methylprednisolone 
125 mg), and 5 mL of saline to guide epicardial mapping and 
minimize pericardial inflammation. Pericardiogram can be 
very useful for identifying important structures for future th-
erapy. For example, the left atrial appendage can be easily vi-
sualized with fluoroscopy and can be a useful guide for epi-
cardial ligation of the left atrial appendage to prevent throm-
boembolic events during atrial fibrillation. The pericardio-
gram can also be used to guide mapping catheter manipul-
ation as shown in Fig. 9. The catheter or instruments can be 
manipulated manually or with an external magnetic field gu-
ided system, which may increase the accuracy and safety. 
During the procedure, blood pressure monitoring is impor-
tant. If the systolic blood pressure drops more than 10 mmHg, 
the operator needs to rule out excessive pericardial fluid ac-
cumulation. This is especially important during open irrigat-
ed catheter ablation of cardiac arrhythmias. On occasion, we 
deliberately fill the pericardial space with 150 mL of saline 
to expand the pericardial space during epicardial ablation, 
in order to minimize collateral organ injuries (such as to the 
lungs, nerves, and esophagus). 
Post-procedure care 
After completion of the procedure, the sheath is gently as-
pirated to remove excess fluid, and to confirm the absence of 
bleeding. Generally, no major re-accumulation of pericardial 
fluid is observed following post-procedure draining of the 
pericardial fluid. Transthoracic echocardiogram is used to 
confirm complete drainage then the sheath is removed. We 
had a few patients who experienced persistent pericardial flu-
id drainage after the epicardial ablation procedure that re-
quired a “pig-tail” drainage catheter placement through the 
sheath, but usually drainage tapered quickly over the subse-
quent 24 to 48 hour period. 
Fig. 6. Puncture technique 2. A: the left anterior oblique view is helpful to confirm the anterior versus posterior orientation of the needle (right and 
left cardiac chambers). B: the right anterior oblique view helps to confirm the superior and inferior orientation (atria and ventricles). C: if the pene-
tration of the parietal pericardium is felt, a small volume (<1 mL) of contrast is injected into the pericardial space to confirm a successful punc-
ture. D: a long soft “J” tip guide wire is advanced far enough to silhouette the pericardial space.
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The catheter could be removed without any complications 
or re-accumulation. It is important to continue oral steroid and 
IV antibiotic therapy, and perform follow up echocardiogram 
studies in these patients.
Cardiac Therapies  
via a Closed Pericardium
Catheter ablation
There has been extensive data on open chest surgical abla-
tion for ischemic ventricular tachycardia (VT) since the late 
1980’s, but subsequent development of implantable cardio-
verter defibrillator and percutaneous epicardial catheter ab-
lation has drastically reduced the need for this technique in 
cardiac electrophysiology. 
The first successful catheter based epicardial ablation of 
ischemic VT was reported by Sosa et al.
30) Since then a larger 
number of cases of successful ablation has been reported.
31) 
Subsequently, the safety and techniques for an efficient abla-
tive energy delivery in the pericardial sac where cooling of 
the catheter tip is limited have been reported.
32)33) Epicardial 
ablation has been shown to be essential in patients with VT 
related to structural heart disease, including ischemic heart 
disease, dilated cardiomyopathy, amyloidosis, and inherit-
able diseases such as arrhythmogenic right ventricular dys-
plasia.
34) Recently, the pericardial approach has also been 
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Fig. 7. Puncture technique 3. A and B: after removing the puncture needle, an 8F dilator is advanced over the guide wire under fluoroscopy to achi-
eve pre-dilatation. C and D: the long sheath with the dilator is advanced or manipulated with the guide wire to reach the target area and then the 
dilator is removed.
Fig. 8. Right anterior oblique projection of a pericardiogram used to 
guide the epicardial mapping. A: groove between the aorta and su-
perior vena cava. B: pulmonary artery. C: left atrial appendage. D: ri-
ght atrial appendage. E: inferior wall of the left ventricle. F: anterior wall 
of the left ventricle.486   Percutaneous Epicardial Therapies
used to map and ablate non-cardiac tissue that plays an im-
portant role in triggering arrhythmia, such as the cardiac gan-
glionic plexi.
35) Epicardial ablation via the pericardial approa-
ch has brought about higher success rate and safety in many 
cases that failed with endocardial ablation.
Hybrid approach
If the patient is unsuitable for percutaneous epicardial 
procedure due to previous cardiac surgery, catheter ablation 
can be performed via a pericardial window assisted by a sur-
gical team in a hybrid laboratory setting of cardiac surgery 
and electrophysiology. There have been several case reports 
using this hybrid approach with good outcomes.
36)
 
Drug delivery
There are many different cardiac drugs that have been de-
livered safely into the pericardial space, but the majority of 
these studies involving those drugs were conducted using the 
direct delivery methods via the open chest model in animals, 
or during cardiac surgery.
37-41) The beneficial effects of nitric 
oxide and nitroprusside in ischemic animal model have been 
well studied.
42)43) Zipes
44) investigated voltage-sensitive chem-
icals for targeting depolarized cells in an ischemic model and 
calcium-avid cells that seek intracellular calcium. A myosin 
antibody loaded with anti-arrhythmic agents has been deliv-
ered via the pericardial space to demonstrate the efficacy. 
Avitall et al.
45) used iontophoresis to enhance drug efficacy via 
the pericardial space. 
Limited data is available on the closed pericardial sac mod-
el, especially in cardiac patients.
46) Uchida et al.
47) successful-
ly delivered fibroblast growth factor into the pericardial space 
in an acute ischemic model to promote successful angiogenesis. 
Laham et al.
48) were also able to demonstrate successful 
angiogenesis effects of a bFGF delivery via a closed pericar-
dial sac in ischemic heart disease patients. Closed pericardial 
sac drug therapy offers many advantages over the open chest 
model. Apart from safety and complication issues, a much 
higher local drug concentration can be achieved above the 
systemic tolerance range by intrapericardial delivery, and spe-
cific drugs that target the epicardium will be more effective.
49)
Future Developments
Safety and technologies
The procedural environment needs to be defined and new 
tools need to be developed to improve safety and facilitate 
the procedure. A small caliber flexible non-traumatic scope 
that visualizes the entire procedure via a small subxyphoid 
incision would be ideal for assisting puncture of a closed peri-
cardial sac. A large diameter scope is likely to increase peri-
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Fig. 9. The location of possible epicardial mapping. The mapping catheter (duodecapolar) is located in the crux of the heart (A), sulcus terminalis 
(B), sinus node (C), junction of the superior vena cava and right atrium (D), superior sinus at the 3rd fat pad (E), and ligament of Marshall (F).Seongwook Han, et al.   487
cardial inflammation, trauma, and scar tissue that can cause dif-
ficulties in future procedures. Tool design may vary according 
to the intended therapy, but a single device for multi-purpose 
use would be ideal for minimizing the cost and facilitating 
learning. 
Future Procedures
in Cardiac Therapies
Electrophysiology and pacing
Magnetic field guided robotic, epicardial mapping and 
ablation
The currently available or upcoming magneto-robotic sys-
tems for guiding ablation catheter can be applied in the peri-
cardial procedure. The limited experience, including ours, 
has shown that the mobility of the catheter is much smooth-
er and easier to manipulate in the pericardial space than that 
when accessed from the endocardium. An epicardial appro-
ach using a robotic system in suitable patients should be saf-
er and more effective.
Epicardial left atrial appendage ligation for stroke 
prevention
Several techniques and technologies are available for left 
atrial appendage closure to prevent strokes via the endocar-
dial or epicardial approaches. Leithauser and Park
50) in a pre-
vious issue of this journal extensively reviewed the endovas-
cular approaches and discussed their limitations. From the 
cardiac arrhythmia stand point, the epicardial ligation tech-
nique published by Friedman et al.
51) is the most attractive, 
since it can also isolate the left atrial appendage electrically. 
Pacemaker lead placement
Wireless pacemaker technologies have gained intense in-
terest from many private industries, and this technology can 
offer a variety of advantages. Pericardial pacing with this 
technology would no longer be cardiac structure dependent, 
and could create pacing close to that of true physiologic con-
dition, especially for re-synchronization purposes.
Biological therapies
The first successful catheter-based pericardial gene trans-
fer mediated by adenoviral vectors was reported by March et 
al.
52) Furthermore, direct epicardial gene delivery of skeletal 
muscle Na+ channel genes to improve Na+ channel function 
of diseased myocardial cells was shown to be effective in sup-
pressing VT in a canine myocardial infarction model.
53) That 
study used an open chest model to deliver genes with the 
paintbrush technique. The study demonstrated the feasibili-
ty of delivering other types of biological agents, such as cells 
and genetically engineered tissue for regenerative as well as 
anti-arrhythmic therapy purposes. Brugada syndrome would 
be an excellent model for gene transfer therapy via the peri-
cardial space. The majority of these patients have structural-
ly normal hearts, albeit with specific ion channel mutations 
that primarily affect the epicardium of right ventricular out 
flow tract. In addition, biological pacemaker therapy for the 
sick sinus syndrome could be an excellent study model for 
pericardial therapy, since the sinus node is primarily an epi-
cardial structure and a closed pericardial sac that offer a bet-
ter environment for biological pacemaker cells to anchor to 
the target tissue.
54) However, the delivery of biological agents 
is the subject of ongoing investigation and is still far from 
clinical practice.
Conclusions
Percutaneous access to a closed pericardium is feasible 
and safe, and epicardial therapy has unique advantages in the 
variety of treatment modalities and lack of anatomical limi-
tations. It should lead a shift in the treatment paradigm in the 
near future. However, percutaneous pericardial access re-
quires extremely skilled technique and much operator expe-
rience. There is need for further refinement of the technique, 
design and development of dedicated equipment, and estab-
lishment of effective facilities. 
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